Antineural and antinuclear autoantibodies are of prognostic relevance in non- small cell lung cancer

Annals of Thoracic Surgery

Volumn 69, Issue 1, 2000, Pages 254-258

  Blaes, Franz ^b   Klotz, Markus ^a   Huwer, Hanno ^a   Straub, Uwe ^a   Kalweit, Gerhard ^a   Schimrigk, Klaus ^a   Schäfers, Hans Joachim ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY;

AGED; ANTIBODY DETECTION; AUTOIMMUNITY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CEREBELLUM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0033981030     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)01198-4     Document Type: Conference Paper

References (23)

1. Mountain C.F. A new international staging system for lung cancer. Chest. 89:(Suppl):1986;225-233.
2. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 96:1988;440-447.
3. Fielding L.P. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer. 69:1992;1592-1599.
4. Dalmau J., Furneaux H.M., Cordon-Cardo C., Posner J.B. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol. 141:1992;881-886.
5. Dalmau J., Furneaux H.M., Gralla R.J., Kris M.G., Posner J.B. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer a quantitative western blot analysis . Ann Neurol. 27:1990;544-552.
6. Graus F., Dalmau J., Reñé R., et al. Anti-Hu antibodies in patients with small cell lung cancer association with complete response to therapy and improved survival . J Clin Oncol. 15:1997;2866-2872.
7. Tanaka K., Yamazaki M., Sato S., Toyoshima I., Yamamoto A., Miyatake T. Antibodies to brain proteins in paraneoplastic cerebellar degeneration. Neurology. 36:1986;169-172.
8. Mountain C.F. Surgical treatment of lung cancer. Crit Rev Oncol Hematol. 11:1991;179-207.
9. Thomas P., Rubinstein L. Cancer recurrence after resection T1N0 non-small cell lung cancer . Ann Thorac Surg. 49:1990;242-247.
10. Martini N., Bains M.S., Burt M.E., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 109:1995;120-129.
11. Sugio K., Ishida T., Yokoyama H., et al. Ras gene mutations as a prognostic marker in adenocarcinoma of the lung without lymph node metastasis. Cancer Res. 52:1992;2903-2906.
12. Kawashima K., Nomura S., Hirai H., et al. Correlation of L-myc RFLP with metastasis, prognosis and multiple cancer in lung-cancer patients. Int J Cancer. 50:1992;557-561.
13. Kandioler D., Foedinger M., Mueller M.R., Eckersberger F., Mannhalter C., Wolner E. Carcinogen-specific mutations in the p53 tumor suppressor gene in lung cancer. J Thorac Cardiovasc Surg. 107:1994;1095-1098.
14. Wiman K.G. p53 emergency brake and target for cancer therapy . Exp Cell Res. 237:1997;14-18.
15. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:1993;2379-2385.
16. Van Zandwijk M., Jassem E., Bonfrèr J.M.G., et al. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol. 19:1992;37-43.
17. Klotz M., Blaes F., Funke D., Kalweit G., Schimrigk K., Huwer H. Shift in the IgG subclass distribution in patients with lung cancer. Lung Cancer. 24:1999;25-30.
18. Hodson M.E., Turner-Warwick M. Autoantibodies in patients with bronchial carcinoma. Thorax. 30:1975;367-370.
19. Yamamoto A., Shimizu E., Ogura T., Sone S. Detection of autoantibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer. 69:1996;283-289.
20. Lubin R., Zalcman G., Bouchet L., et al. Serum p53 antibodies as early markers of lung cancer. Nature Med. 1:1995;701-702.
21. Winter S., Sekido Y., Minna J., et al. Antibodies against autologous tumor cell proteins in patients with small cell lung cancer association with improved survival . J Natl Cancer Inst. 85:1993;2012-2018.
22. Verschuuren J.J., Dalmau J., Hoard R., Posner J.B. Paraneoplastic anti-Hu serum studies on human tumor cell lines . J Neuroimmunol. 79:1997;202-210.
23. Albert M.L., Darnell J.C., Bender A., Francisco L.M., Bhardwaj N., Darnell R.B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Med. 4:1998;1321-1324.